QT Imaging Holdings, Inc
QT Imaging Holdings, Inc. develops and commercializes the QT Breast Scanner, a breast imaging system used in medical settings for screening and diagnostic workflows. The company is based in the United States and operates through a mix of direct sales and distribution partners, with products, software, accessories, and related services tied to its imaging platform.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2021–2025
Liiketoiminta
Osuus liikevaihdostaQT Breast Scanner hardware used for breast imaging and screening workflows.
Software and cloud-based platform access tied to scanner operation and use.
Scanner accessories and other product add-ons sold with the imaging system.
Customer training for operators and clinical staff using the QT platform.
Ongoing servicing, maintenance, and related support for installed systems.
Tuotteet
Raportoitu · osuus liikevaihdosta- Products99,1 %
- Services0,9 %
Lähde: 10-K FY2025, yhtiön tuotelinjoittain raportoima liikevaihto (SEC XBRL). Osuudet on laskettu näytetyistä riveistä ja ne summautuvat 100 %:iin.
Asiakkaat
Customers are hospitals, radiology centers, clinics, and other medical providers that use breast imaging equipment in clinical workflows. The company also sells through distributors and sales agents, including exclusive arrangements in the U.S. and selected international markets, which broadens access to end users while keeping direct sales optional.
Buy QT Breast Scanners for inpatient and outpatient breast imaging workflows.
Purchase scanners to expand breast imaging capacity and diagnostic offerings.
Use the system for breast screening and referral-based diagnostic imaging.
Resell, lease, or rent the scanners and help reach local healthcare buyers.
Buy through designated territories such as U.S. Department of Defense sites.
Strategia
The company’s strategy is to commercialize the QT Breast Scanner through product innovation, clinical adoption, and partner-led distribution. It also emphasizes internal manufacturing capability and strategic manufacturing partnerships to support broader scale-up and market access.
The business depends on hospitals and radiology centers accepting a new imaging platform.
Partner channels help reach buyers faster than a direct-only sales model.
Imaging quality, usability, and analytics support differentiation and repeat use.
Broader commercialization requires reliable production, fulfillment, and support.
Maantiede
QT Imaging is centered on the U.S. market, where its distribution agreement covers the United States and U.S. territories, while the company retains the ability to sell elsewhere globally. The reports also reference planned expansion into other regions and a Saudi Arabia distribution agreement, indicating an early international commercialization footprint.
Riskit
QT Imaging faces the risks typical of an early-stage medical device company, including limited operating history, adoption uncertainty, and the need for regulatory and clinical acceptance. Its partner-led sales model, debt obligations, and dependence on trained radiologists and suppliers add execution risk, while product, IP, and data-security issues can affect commercialization and trust.
- Market acceptance of the QT Breast ScannerVaikutus: KorkeaTodennäköisyys: Korkea
Revenue depends on buyers adopting a new imaging platform at acceptable prices.
Kohdistuu - Capital and debt repayment riskVaikutus: KorkeaTodennäköisyys: Korkea
The company must fund operations and meet debt cash obligations as they come due.
Kohdistuu: Liquidity and financing capacity
- Regulatory and product clearance riskVaikutus: KorkeaTodennäköisyys: Kohtalainen
Additional FDA clearances may be needed for current and future products.
Kohdistuu: Medical device approvals
- Training and workflow adoption by radiologistsVaikutus: Korkea
Customers need trained professionals to review and use the images effectively.
Kohdistuu: Clinical end users and interpreting physicians
- Dependence on distribution partnersVaikutus: KeskitasoTodennäköisyys: Korkea
Sales execution relies on reseller and agent relationships that may not perform as expected.
Kohdistuu: NXC and other distribution agreements
- Intellectual property protectionVaikutus: KeskitasoTodennäköisyys: Matala
The company’s differentiation depends on protecting imaging technology and related know-how.
Kohdistuu
Kirjanpito
Harkinnanvaraiset erätScanner sales are point-in-time, while training and maintenance are service-based.
Vaikutus: Affects timing of reported revenue and gross margin
Warrant, derivative, and earnout liabilities are revalued each period.
Vaikutus: Can create large non-cash gains or losses in net income
Manufacturing, shipping, and replacement obligations require judgment.
Vaikutus: Affects cost of revenue and reported gross profit
Small order counts can make period-to-period comparisons uneven.
Vaikutus: Can cause volatility in revenue and operating results
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Qt Group Oyj
QTCOM · Software - Application
Qt Group is a software company specializing in cross-platform development tools for embedded systems and applications.
iRhythm Holdings, Inc.
IRTC · Surgical & Medical Instruments & Apparatus
IR-Med, Inc.
Electromedical & Electrotherapeutic Apparatus
Quest Diagnostics Incorporated
DGX · Services-Medical Laboratories
Quest Diagnostics is a U.S.-based clinical laboratory company that provides diagnostic testing, pathology, and related information services through a…
iHeartMedia, Inc.
IHRT · Radio Broadcasting Stations
Quanterix Corp
QTRX · Laboratory Analytical Instruments
Quanterix Corp develops and commercializes ultra-sensitive life science instruments, assay kits, and related services used to measure proteins and biomarkers in biological samples.
Päivitetty: 24.9.2026